HVG

Hearing voices? You’re not alone

Retrieved on: 
Wednesday, June 21, 2023

It is estimated that 13.2% of the adult general population are subject to it, yet this experience still carries much stigma.

Key Points: 
  • It is estimated that 13.2% of the adult general population are subject to it, yet this experience still carries much stigma.
  • For several decades now, the international Hearing Voices Movement (HVM) has been campaigning to improve the way this condition is perceived.

Changing textbooks

    • Our entire culture teaches us that the ego must remain master of its own house.
    • In psychiatry, hearing voices in the absence of external inputs is equated with hallucination, a clear expression of psychosis.
    • But even psychiatric textbooks are changing.

Less lonely together

    • Since the 1980s, a growing number of people have confessed to “hearing voices”.
    • All have managed to tap into a range of resources to deal with their experiences, without necessarily turning to psychiatry.

Inclusive change

    • Its members prefer to consider that voices are real, carry meaning and links to trauma – even if opinions differ as to their explanations.
    • It’s all part of the trend toward health care patient and provider empowerment, which has been recommended by the World Health Organisation.

The groups’ effectiveness

    • A questionnaire designed jointly with English voice hearers has been adapted into French.
    • The study compared the effects of VHGs with those of ordinary therapeutic groups.
    • As the study took place during the Covid-19 pandemic, the groups ran slowly and only 20 of the 50 in France completed the study.

Different methods, similar results

    • In parallel, a 14-person control group underwent metacognitive training, a method aimed at helping people with psychosis become more aware of thinking patterns contributing to their symptoms.
    • VHGs hold the advantage of attracting people who do not have a psychiatric diagnosis or who do not fully accept it.
    • Ultimately, VHGs’ value lies not so much in their ability to replace existing treatments as to complement them.

In the minds of carers

    • Surveying 79 staff from French mental health institutions, the second study confirmed the medical and caring personnel largely views them positively.
    • The more professionals familiarise ourselves with these structures, the more they stand to free themselves from such stereotypes.

Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022

ET today

Key Points: 
  • ET today
    SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (Gracell or Company), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported third quarter unaudited financial results for the period ended September 30, 2022, and provided corporate updates.
  • First clinical data from ongoing IIT evaluating GC012F in NDMM patients to be presented as oral session at ASH 2022.
  • On track to submit the IND applications in the U.S. and China in the fourth quarter 2022 to evaluate GC012F for the treatment of RRMM.
  • Gracell specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise.

HealthValue Group Executes COVID-19 Testing FMV Benchmarks to Avoid Kickback Lawsuits

Retrieved on: 
Thursday, September 22, 2022

Denver, Colorado--(Newsfile Corp. - September 22, 2022) - Denver-based healthcare fair market value (FMV) and appraisal firm HealthValue Group has implemented COVID-19 testing FMV benchmarks to help assist labs and specimen collection enterprises with supportable and highly defensible rates for specimen collection services.

Key Points: 
  • Denver, Colorado--(Newsfile Corp. - September 22, 2022) - Denver-based healthcare fair market value (FMV) and appraisal firm HealthValue Group has implemented COVID-19 testing FMV benchmarks to help assist labs and specimen collection enterprises with supportable and highly defensible rates for specimen collection services.
  • These businesses collect samples from patients, then the samples are sent to the actual laboratory for testing.
  • Federal healthcare laws preclude the labs from paying more than fair market value (FMV) for each patient specimen.
  • HealthValue Group, based in Denver, CO, is a healthcare FMV and appraisal firm with clients in over 28 states.

Heath Value Group Implements COVID-19 Testing FMV Benchmarks to Avoid Kickback Lawsuits

Retrieved on: 
Tuesday, September 20, 2022

Denver, Colorado--(Newsfile Corp. - September 20, 2022) - Denver-based healthcare fair market value (FMV) and appraisal firm Heath Value Group has implemented COVID-19 testing FMV benchmarks to help assist labs and specimen collection enterprises with supportable and highly defensible rates for specimen collection services.

Key Points: 
  • Denver, Colorado--(Newsfile Corp. - September 20, 2022) - Denver-based healthcare fair market value (FMV) and appraisal firm Heath Value Group has implemented COVID-19 testing FMV benchmarks to help assist labs and specimen collection enterprises with supportable and highly defensible rates for specimen collection services.
  • These businesses collect samples from patients, then the samples are sent to the actual laboratory for testing.
  • Federal healthcare laws preclude the labs from paying more than fair market value (FMV) for each patient specimen.
  • Health Value Group, based in Denver, CO, is a healthcare FMV and appraisal firm with clients in over 28 states.

Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 15, 2022

ET today

Key Points: 
  • ET today
    SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (Gracell or Company), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported second quarter unaudited financial results for the period ended June 30, 2022, and provided corporate updates.
  • Updated data from single-arm, open-label IIT with longer follow-up of GC502 in r/r B-ALL presented at EHA 2022.
  • Financial Results for the Second Quarter Ended June 30, 2022
    As of June 30, 2022, the Company had RMB1,707.3 million (US$254.9 million) in cash and cash equivalents and short-term investments.
  • Gracell specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise.

35th Maschsee Lake Festival Hannover 2022: A culinary and artistic voyage around the world

Retrieved on: 
Friday, July 15, 2022

The international Big 7 Travel portal has selected the Maschsee Lake Festival Hannover as the only German summer festival in the TOP 10 Food Festivals.

Key Points: 
  • The international Big 7 Travel portal has selected the Maschsee Lake Festival Hannover as the only German summer festival in the TOP 10 Food Festivals.
  • The Maschsee Lake Festival Hannover was awarded the ninth place in the selection procedure published at the start of June.
  • The 35th edition of the Maschsee Lake Festival Hannover will live up to this accolade in full, with this year's range of offerings, and in particular the new culinary concepts.
  • Lindenblatt goes Maschsee Lake Festival Hannover: In collaboration with Aresto, the best from the restaurants "800 Grad" und "Lokal 4" come together at the Maschsee Lake Festival Hannover.

Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence

Retrieved on: 
Thursday, June 30, 2022

Cellectis next generation of universal CAR T-cells have the potential to improve the persistence and to allow large-scale deployment of T-cell product candidates in allogeneic settings against multiple malignancies.

Key Points: 
  • Cellectis next generation of universal CAR T-cells have the potential to improve the persistence and to allow large-scale deployment of T-cell product candidates in allogeneic settings against multiple malignancies.
  • Universal CAR T-cell therapies are poised to revolutionize the treatment of selected hematologic malignancies.
  • This could enable the broad use of universal CAR T-cells in allogeneic settings, for the benefit of a wider population of patients, said Julien Valton, Ph.D., Vice President Gene Therapy at Cellectis.
  • Immune-evasive universal CAR T-cells overcame alloresponsive T-cell and NK cells attacks and exhibit prolonged antitumor activity, even in the presence of highly active NK cells.

Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 16, 2022

ET today

Key Points: 
  • ET today
    SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, May 16, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (Gracell or Company), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported first quarter unaudited financial results for the three months ended March 31, 2022, and provided corporate updates.
  • Plan to submit the U.S. and China IND filings for RRMM in the second half of 2022.
  • First-in-human data from China IIT study in B-ALL patients were presented at AACR on April 12, 2022.
  • Gracell specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise.

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress

Retrieved on: 
Thursday, May 12, 2022

"The new data, including the expanded indication of GC012F into B-NHL, demonstrates the potential of our platforms and provides further validation.

Key Points: 
  • "The new data, including the expanded indication of GC012F into B-NHL, demonstrates the potential of our platforms and provides further validation.
  • The CD19/CD7 dual-directed CAR-T therapy GC502 is our second allogeneic candidate on our TruUCAR platform, demonstrating the potential wide applicability of the TruUCAR design."
  • Gracell will present the early results of the first-in-human phase 1 IIT in China evaluating the safety and tolerability of GC012F in B-NHL patients.
  • Three patients who had received a median of two prior lines of therapy were enrolled, all of which presented with bulky disease.

Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL

Retrieved on: 
Friday, April 8, 2022

PALO ALTO, Calif. and SUZHOU, China, April 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the early results of a first-in-human clinical study of GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Gracell will share the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 12.

Key Points: 
  • Gracell will share the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 12.
  • "We are very excited to present our data on GC502 at this year's AACR annual meeting.
  • CD19 is a validated target in the treatment of r/r B-ALL," said Dr. Martina Sersch, Chief Medical Officer of Gracell.
  • The early results show the potential of GC502 and warrant further evaluation in the ongoing clinical investigator-initiated-trial (IIT).